Octapharma redford The Redford plant focuses on the production of immunoglobulin products, which are plasma-derived medicines used to treat various immune deficiencies and neurological disorders. These products are derived from human plasma, which is collected through a network of donation centers. The plasma is then transported to the Redford facility for further processing and manufacturing. Octapharma Redford is equipped with state-of-the-art technology and follows stringent quality control measures to ensure the safety and efficacy of its products. The facility is compliant with all current Good Manufacturing Practices (cGMP) and is regularly inspected by the U.S. Food and Drug Administration (FDA) and other international regulatory bodies. The plant also adheres to Octapharma's global quality standards, which are designed to ensure consistent product quality across all its manufacturing sites. The Redford facility employs a large number of people from the local community, contributing to the economic growth of the region. The company is committed to creating a positive work environment and offers various training and development programs to its employees. Octapharma also participates in community initiatives and supports local charities, further solidifying its presence in Redford, Michigan. In addition to its Redford facility, Octapharma has manufacturing sites in Austria, France, Germany, and Mexico. This global presence allows the company to meet the diverse needs of its customers and respond quickly to changes in market demand. Octapharma's commitment to innovation and quality has made it a leader in the plasma protein therapeutics industry, and its Redford facility plays a crucial role in this success. Octapharma Redford is a manufacturing facility located in Redford, Michigan, owned by the Swiss-based pharmaceutical company, Octapharma AG. This facility is one of the many production sites of Octapharma, which specializes in the development and manufacture of human proteins for therapeutic use. In addition to its Redford facility, Octapharma has manufacturing sites in Austria, France, Germany, and Mexico. This global presence allows the company to meet the diverse needs of its customers and respond quickly to changes in market demand. Octapharma's commitment to innovation and quality has made it a leader in the plasma protein therapeutics industry, and its Redford facility plays a crucial role in this success.
The company also places a strong emphasis on patient safety. Reliant Immediate Care Medical Group Inc. follows strict protocols to ensure that its facilities are clean and sanitary, and that all medical equipment is properly sterilized. In addition, the company's medical professionals receive ongoing training to ensure that they are up-to-date on the latest medical practices and procedures. Conclusion: